Compare OLP & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLP | CAPR |
|---|---|---|
| Founded | 1982 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 550.9M | 584.9M |
| IPO Year | 1995 | 2011 |
| Metric | OLP | CAPR |
|---|---|---|
| Price | $23.10 | $8.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $26.75 | ★ $44.63 |
| AVG Volume (30 Days) | 50.1K | ★ 7.5M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 7.88% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $82,740,000.00 | N/A |
| Revenue This Year | $11.98 | N/A |
| Revenue Next Year | $3.71 | $3.31 |
| P/E Ratio | $23.20 | ★ N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $19.62 | $2.96 |
| 52 Week High | $25.88 | $40.37 |
| Indicator | OLP | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 37.19 | 47.13 |
| Support Level | $23.31 | $3.35 |
| Resistance Level | $23.63 | $11.00 |
| Average True Range (ATR) | 0.42 | 0.94 |
| MACD | -0.08 | 0.30 |
| Stochastic Oscillator | 16.42 | 42.93 |
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred and two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.